222,615 Shares in Beta Bionics, Inc. $BBNX Purchased by Essex Investment Management Co. LLC

Essex Investment Management Co. LLC bought a new stake in Beta Bionics, Inc. (NASDAQ:BBNX) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 222,615 shares of the company’s stock, valued at approximately $4,423,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. GPS Wealth Strategies Group LLC increased its stake in shares of Beta Bionics by 45.0% during the 3rd quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock worth $29,000 after purchasing an additional 450 shares during the last quarter. New York State Common Retirement Fund grew its holdings in Beta Bionics by 617.6% during the third quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock valued at $242,000 after purchasing an additional 10,500 shares during the period. Rakuten Investment Management Inc. purchased a new stake in Beta Bionics in the third quarter worth $706,000. Calamos Advisors LLC bought a new stake in shares of Beta Bionics in the third quarter valued at $642,000. Finally, Soleus Capital Management L.P. raised its stake in shares of Beta Bionics by 12.5% in the second quarter. Soleus Capital Management L.P. now owns 3,820,158 shares of the company’s stock valued at $55,622,000 after buying an additional 424,817 shares during the period.

Analyst Ratings Changes

BBNX has been the subject of several research reports. Stifel Nicolaus cut their price target on Beta Bionics from $31.00 to $25.00 and set a “buy” rating for the company in a research note on Wednesday, February 4th. UBS Group started coverage on shares of Beta Bionics in a report on Sunday. They set a “buy” rating and a $24.00 price objective on the stock. Piper Sandler reiterated an “overweight” rating and issued a $32.00 target price (up previously from $26.00) on shares of Beta Bionics in a research note on Wednesday, October 29th. The Goldman Sachs Group reissued a “buy” rating and issued a $25.00 price target on shares of Beta Bionics in a research report on Thursday, January 15th. Finally, Bank of America downgraded shares of Beta Bionics from a “buy” rating to a “neutral” rating in a report on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $26.42.

Insider Buying and Selling

In other Beta Bionics news, CFO Stephen Feider sold 20,000 shares of the stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $29.53, for a total value of $590,600.00. Following the sale, the chief financial officer directly owned 42,614 shares in the company, valued at $1,258,391.42. This represents a 31.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Mike Mensinger sold 7,800 shares of the firm’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $29.61, for a total transaction of $230,958.00. Following the completion of the transaction, the insider directly owned 82,952 shares of the company’s stock, valued at approximately $2,456,208.72. The trade was a 8.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 32,490 shares of company stock valued at $960,835 over the last 90 days.

Beta Bionics Stock Up 6.0%

BBNX stock opened at $13.87 on Tuesday. The firm has a market capitalization of $610.70 million and a PE ratio of -3.17. Beta Bionics, Inc. has a twelve month low of $8.89 and a twelve month high of $32.71. The stock has a 50-day simple moving average of $23.92 and a two-hundred day simple moving average of $22.66.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.